GlassScriptPrepare for your visit
Daniel Jacob Riboh
Medical · North Hollywood, CA · NPI 1255046603
One page to bring to your appointment. Every figure is as reported to CMS by drug and device makers. Payments are legal and often routine; this is context for a conversation, not a verdict.
What was reported
$1,042.99
in general payments reported to CMS, 2019-2025 · $778 in 2025
The $778 reported for 2025 was more than what 76% of Medical providers received nationally (typical 2025 total: $213).
Who reported paying
General payments only, top 6 by amount.
- Amgen INC. $362.16
- Dexcom, INC. $240.74
- Novo Nordisk INC $117.87
- Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) $94.15
- Lilly USA, LLC $82.02
- Teva Pharmaceuticals USA, INC. $59.22
Drugs and devices associated with these payments
Repatha Dexcom G6 Transmitter Otezla Caplyta Wegovy Austedo Xr Zepbound Mounjaro Immunocap Thinprep 2000 Processor Aptima Ubrelvy
Association is not allocation: a product listed here means a payment was associated with it, not that money was paid to promote it. Detail covers 2023-2025.
Questions you might ask
- I saw Daniel Riboh listed in the CMS Open Payments database. Can you tell me about your work with those companies?
- Is there a generic or alternative to this medication, and would it work as well for me?
- What made you choose this particular treatment for my situation?
These are normal questions. A good clinician will welcome them.
Notes
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.
GlassScript is independent and not affiliated with CMS or any government agency. glasscript.com/doctor/11605160/daniel-jacob-riboh